hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang上一页:特发性癫痫大发作药物治疗的首选
下一页:癫痫患者手术评估新型工具
- 2022-04-252013年国际抗癫痫联合会抗癫痫制剂使用指南
- 2022-04-13手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 2022-04-12由于医生的原因,物「沉默」而且很难进入处方
- 2022-04-11癫痫治疗障碍仍难以克服
- 2022-04-07银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 2022-04-06【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 由于医生的原因,物「沉默」而且很难进入处方
- FDA批准Aptiom用于治疗患者癫痫发作
- 癫痫治疗障碍仍难以克服
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- UCB的Vimpat癫痫新适应症在美国获批
- 预测癫痫患者再入院风险
- 2015第31届国际癫痫大会(IEC)
- 2015 神经系统疾病诊疗进展
- 如何诊断最科学
- 20首款慢性肾脏病治疗药物Forxiga获得NICE推荐
- 癫痫患者手术评估新型工具
- 2013国际抗癫痫联合会抗癫痫药用指南
- 特发性癫痫大发作药物治疗的首选
- 高考食谱 吃对食物,实现高考梦(13)
- 癫痫猝死:凶手是谁?
- 预防银屑病复发的措施
- 月经性癫痫患者妊娠期癫痫控制更好
- Medpage Today:不同类型的抗癫痫药物更有利
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 不注意这些问题,吃多少药都没用!
- Clin Gastroenterology?H:?多潘立酮治疗对胃轻瘫症状的影响
- 三庚酸酯可治疗1型转运体缺陷综合征
- 儿童癫痫的早期症状 癫痫的原因
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 四大饮食改善患者病情
- 女性癫痫病的怎么疗程
- 治疗法癫痫病最佳
- AAN/AES发布新版首次非诱发性癫痫发病诊疗指南
- 癫痫疾病的检查诊断方法有哪些 癫痫疾病的检查费用很高吗
- 早期癫痫病症状平庸是什么
- 引发癫痫病的病因有哪些?
- 不同长庚卒中量表的评估比较
- 癫痫病发作时有哪些呕吐
- 小儿癫痫病症治疗需注意的事项
- 肺源性心脏病可能并发左心功能不全吗?如何制定治疗法方案?
- 怎么用生物科学的方法治疗癫痫病
- 儿童癫痫病的患病症状都有哪些